Quarterly Financial Supplement FOR THE PERIOD ENDED MARCH 31, 2025 Beachwood, OH 44122 216-755-5500 SITE Centers Corp. For additional information: 3300 Enterprise Parkway Gerald Morgan, EVP and Chief Financial Officer FOR IMMEDIATE RELEASE: SITE Centers Reports First Quarter 2025 Results Beachwood, Ohio, May 7, 2025 - SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers located primarily in suburban, high household income communities, announced today operating results for the quarter ended ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-11690 SITE Centers Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization ...

Exhibit 99.1 Exhibit 99.1 SITE Centers Corp. Table of Contents | Section | Page | | --- | --- | | Earnings Release & Financial Statements | | | Press Release | 1-6 | | Company Summary | | | Portfolio Summary | 7 | | Capital Structure and Debt Detail | 8 | | Leasing Summary | 9 | | Lease Expirations | 10 | | Top 30 Tenants | 11 | | Unconsolidated Joint Ventures | | | Unconsolidated Joint Ventures | 12-14 | | Shopping Center Summary | | | Property List | 15 | | Reporting Policies and Other | | | Notable Accou ...

SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors in San Diego, March 12-14. In the poster, titled, “T ...

Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 For the transition period from to Commission file number 1-11690 SITE Centers Corp. (Exact Name of Registrant as Specified in Its Charter) Ohio 34-1723097 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 3300 Enterprise Parkway, Beachwoo ...

For the quarter ended December 2024, SITE CENTERS CORP. (SITC) reported revenue of $32.87 million, down 73.3% over the same period last year. EPS came in at $0.16, compared to $3.68 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $42.65 million, representing a surprise of -22.94%. The company delivered an EPS surprise of -30.43%, with the consensus EPS estimate being $0.23.While investors closely watch year-over-year changes in headline numbers -- revenue and earning ...

SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.16 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to FFO of $1.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an FFO surprise of -30.43%. A quarter ago, it was expected that this company would post FFO of $0.87 per share when it actually produced FFO of $0.81, delivering a surprise of -6.90%.Over the last four quarters, the compa ...

Exhibit 99.1 SITE Centers Corp. Table of Contents | Section | Page | | --- | --- | | Earnings Release & Financial Statements | | | Press Release | 1-6 | | Company Summary | | | Portfolio Summary | 7 | | Capital Structure and Debt Detail | 8 | | Leasing Summary | 9 | | Lease Expirations | 10 | | Top 30 Tenants | 11 | | Investments | | | Transactions | 12 | | Unconsolidated Joint Ventures | | | Unconsolidated Joint Ventures | 13-15 | | Shopping Center Summary | | | Property List | 16 | | Reporting Policies an ...

NEW YORK and VIENNA, Nov. 11, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced that clinical collaborator Alan Ho, MD, PhD, Chief of the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center, presented updated Phase 2 data from a study evaluating eseba-vec in combination with pembrolizumab ...

 Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T PRAME franchise to target solid cancers ACTengine® IMA203 demonstrates 54% cORR, 12.1 months mDOR and 6 months mPFS in heavily pretreated metastatic melanoma patients and >1-year mPFS in patients with deep responses; Company plans to start its randomized-controlled Phase 3 SUPRAME trial in December 2024 to evaluate IMA203 in second-line or later metas ...